Sizing up first-in-class dealmaking in Asia

Asia’s biotechs are casting off the “fast follower” label as they move to first-in-class innovation. Among 111 recent deals analyzed by BioCentury that disclosed a target, 41% involved a first-in-class asset.

The largest cohort involves new modalities against known targets (53%), but in a significant number of deals, buyers and sellers are taking target risk with therapies against molecular targets lacking approved products (37%)...